skip to main content
  • January 03, 2018

    A new study led by TFRI-funded researchers at The Ottawa Hospital (TOH) and the University of Ottawa suggests that a combination of two immunotherapies (oncolytic viruses and checkpoint inhibitors) could be much more successful in treating breast cancer and possibly other cancers.

  • December 12, 2017

    More than 200 cancer researchers attended TFRI's 8th Annual Scientific Meeting in Vancouver on Nov. 4. Photos of the event are now posted, check out the gallery here.

  • December 07, 2017

    This was a big year for the Terry Fox Research Institute: 2017 marked our 10th anniversary. Here are two videos we created to celebrate this milestone, telling the story of TFRI's origins, and how we are achieving Terry Fox's dream of finding cures for cancer through research.

  • November 24, 2017

    For the first time in Canadian history, more than 30 pediatric cancer research and funding organizations have joined forces through Terry Fox PROFYLE, a pan-Canadian project to give children, adolescents and young adults who are out of conventional treatment options another chance to beat their cancer.

  • October 26, 2017

    The B.C. Lung Screen Trial at Vancouver General Hospital is currently recruiting 2,000 individuals from the Lower Mainland who are between 55 and 80 years of age, with at least a 30-pack-years smoking history to take part in a new research project.

  • October 18, 2017

    A pan-Canadian team of cancer researchers has developed a predictive model for detecting early-stage lung cancer in high-risk individuals with significantly greater accuracy than other leading models. This Terry Fox Research Institute study suggests the team’s innovative approach could be considered for use in lung cancer screening programs both in Canada and around the world.

  • September 06, 2017

    TFRI is pleased to announce that it will be presenting a concurrent session (D6 in program) at the upcoming Canadian Cancer Research Conference featuring talks by four outstanding Canadian investigators: Dr. John Bell (OHRI) Dr. John Dick (UHN), Dr. Stephen Lam (BC Cancer Agency), and Dr. Marco Marra (BC Cancer Agency).

  • September 06, 2017

    TFRI’s one-day 8th Annual Scientific Meeting on Saturday, Nov. 4 in Vancouver will feature talks related to the theme of the potential of precision medicine. There will be three plenaries on the subjects of cancer biology, prognostic strategies and therapeutic strategies.

  • September 06, 2017

    The annual Terry Fox Run is just around the corner and our purple-shirted research teams, their friends and families will be out in full force again this year! To date more than 16 teams have confirmed their participation in the upcoming run on Sunday, Sept. 17th.

  • September 06, 2017

    A new study has analyzed hundreds of sequenced medulloblastoma (MB) samples, identifying new targets that could give children with this disease less harmful therapeutic options.

  • September 06, 2017

    A recent study by a prolific TFRI-funded team has demonstrated that disrupting ERG transcriptional activity is sufficient to suppress the major characteristics of ERG-transformed prostate cancers.

  • September 06, 2017

    Ontario cancer researchers have found that an oncolytic virus may lead to a promising new therapy option for patients with peritoneal carcinomatosis, a disseminated intra-abdominal tumour.

  • September 06, 2017

    Diffuse optical spectroscopic texture features can predict breast cancer response to neoadjuvant chemotherapy in locally advanced breast cancer patients before therapy even begins.

  • September 06, 2017

    A team of Canadian cancer researchers has shown that rare, therapy-resistant leukemia stem cells are already present at diagnosis in patients who experience relapses of acute myeloid leukemia (AML).

  • September 06, 2017

    While significant accolades are given to scientists who discover genetic mutations that are linked to cancer, it is equally important to determine factors that are not correlated.

Back to Top